IP Verse

Oral Pharmaceutical Compositions Of Dabigatran Etexilate

Patent No. EP2817000 (titled "Oral Pharmaceutical Compositions Of Dabigatran Etexilate") was filed by Esteve Pharmaceuticals on Feb 21, 2013. The application was issued on Aug 4, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPMay 4, 2022HAMM & WITTKOPP
AERAMay 3, 2022AERA
AERAMay 3, 2022BARDEHLE PAGENBERG SL
GLENMARK PHARMACEUTICALS EUROPEApr 14, 2022SCHLICH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2817000

ESTEVE PHARMACEUTICALS
Application Number
EP13704974A
Filing Date
Feb 21, 2013
Status
Granted And Under Opposition
Jul 2, 2021
Publication Date
Aug 4, 2021
External Links
Slate, Register , Google Patents